tetano
Editor, Senior Moderator
Hum Vaccin Immunother
. 2024 Dec 31;20(1):2394255.
doi: 10.1080/21645515.2024.2394255. Epub 2024 Aug 29. Real-world effectiveness of influenza vaccine against medical-attended influenza infection during 2023/24 season in Ili Kazakh Autonomous Prefecture, China: A test-negative, case-control study
Jia Mi[SUP] 1 [/SUP], Juping Wang[SUP] 2 [/SUP], Luping Chen[SUP] 1 [/SUP], Zihao Guo[SUP] 3 4 [/SUP], Hao Lei[SUP] 5 [/SUP], Marc Kc Chong[SUP] 3 4 [/SUP], Jiangatai Talifu[SUP] 2 [/SUP], Shengmei Yang[SUP] 2 [/SUP], Kamuranni Luotebula[SUP] 2 [/SUP], Maierhaba Ablikemu[SUP] 2 [/SUP], Chunyu Ma[SUP] 6 [/SUP], Wenli Lu[SUP] 6 7 8 [/SUP], Zhaohui Luo[SUP] 9 [/SUP], Chuanfa Liu[SUP] 10 [/SUP], Shengzhi Sun[SUP] 11 [/SUP], Jianghong Dai[SUP] 1 [/SUP], Kai Wang[SUP] 1 12 [/SUP], Kailu Wang[SUP] 3 4 [/SUP], Shi Zhao[SUP] 6 7 8 [/SUP]
Affiliations
In the post-COVID-19 pandemic era, influenza virus infections continuously lead to a global disease burden. Evaluating vaccine effectiveness against influenza infection is crucial to inform vaccine design and vaccination strategy. In this study, we recruited 1120 patients with influenza-like illness (ILI) who attended fever clinics of 4 sentinel hospitals in the Ili Kazakh Autonomous Prefecture, Xinjiang Uygur Autonomous Region, China, from January 1 to April 7, 2024. Using a test-negative design, we estimated influenza vaccine effectiveness (VE) of 54.7% (95% CrI: 23.7, 73.1) against medical-attended influenza infection, with 62.3% (95% CrI: 29.3, 79.8) against influenza A, and 51.2% (95% CrI: 28.7, 83.0) against influenza B. Despite the moderate VE estimated in this study, influenza vaccination remains the most important approach to prevent influenza at the community level.
Keywords: Influenza virus; influenza-like illness; test-negative study; vaccine effectiveness.
. 2024 Dec 31;20(1):2394255.
doi: 10.1080/21645515.2024.2394255. Epub 2024 Aug 29. Real-world effectiveness of influenza vaccine against medical-attended influenza infection during 2023/24 season in Ili Kazakh Autonomous Prefecture, China: A test-negative, case-control study
Jia Mi[SUP] 1 [/SUP], Juping Wang[SUP] 2 [/SUP], Luping Chen[SUP] 1 [/SUP], Zihao Guo[SUP] 3 4 [/SUP], Hao Lei[SUP] 5 [/SUP], Marc Kc Chong[SUP] 3 4 [/SUP], Jiangatai Talifu[SUP] 2 [/SUP], Shengmei Yang[SUP] 2 [/SUP], Kamuranni Luotebula[SUP] 2 [/SUP], Maierhaba Ablikemu[SUP] 2 [/SUP], Chunyu Ma[SUP] 6 [/SUP], Wenli Lu[SUP] 6 7 8 [/SUP], Zhaohui Luo[SUP] 9 [/SUP], Chuanfa Liu[SUP] 10 [/SUP], Shengzhi Sun[SUP] 11 [/SUP], Jianghong Dai[SUP] 1 [/SUP], Kai Wang[SUP] 1 12 [/SUP], Kailu Wang[SUP] 3 4 [/SUP], Shi Zhao[SUP] 6 7 8 [/SUP]
Affiliations
- PMID: 39208849
- DOI: 10.1080/21645515.2024.2394255
In the post-COVID-19 pandemic era, influenza virus infections continuously lead to a global disease burden. Evaluating vaccine effectiveness against influenza infection is crucial to inform vaccine design and vaccination strategy. In this study, we recruited 1120 patients with influenza-like illness (ILI) who attended fever clinics of 4 sentinel hospitals in the Ili Kazakh Autonomous Prefecture, Xinjiang Uygur Autonomous Region, China, from January 1 to April 7, 2024. Using a test-negative design, we estimated influenza vaccine effectiveness (VE) of 54.7% (95% CrI: 23.7, 73.1) against medical-attended influenza infection, with 62.3% (95% CrI: 29.3, 79.8) against influenza A, and 51.2% (95% CrI: 28.7, 83.0) against influenza B. Despite the moderate VE estimated in this study, influenza vaccination remains the most important approach to prevent influenza at the community level.
Keywords: Influenza virus; influenza-like illness; test-negative study; vaccine effectiveness.